NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today reported a net loss of $5.6 million, or $.08 per share, for the third quarter of 2006 compared to a net loss of $4.5 million, or $.06 per share, for the third quarter of 2005. For the nine months ended September 30, 2006, AVANT reported a net loss of $14.2 million, or $.19 per share, compared to a net loss of $14.1 million, or $.19 per share, for the nine months ended September 30, 2005. AVANT reported cash and cash equivalents of $46.7 million at September 30, 2006.
